ADHERIUM LIMITED — Investor Presentation 2021

Apr 29, 2021

==> picture [634 x 332] intentionally omitted <==

Establishing leadership in the rapidly accelerating respiratory remote digital monitoring environment

APRIL 2021

==> picture [191 x 35] intentionally omitted <==

adherium

Establishing leadership in the rapidly accelerating respiratory remote digital monitoring environment

Rapid evolution of telehealth & remote digital monitoring, accelerated by COVID and new reimbursement programs

Well placed with strategy development beyond adherence alone, toward multi-sensor respiratory management ecosystem Potential for software platform leverage with established data portal capability

Good progress made with core data portal refresh & development of physiologically enabled adherence monitoring devices

Progress being made with existing commercial partners & >10 ongoing new partner discussions advancing

Fundraise initiated to progress business toward breakeven target

$1 8 m fundraise to progress beyond 2021 commercial evaluations

opportunity

Telehealth & remote digital management of patients transformed in last 24 months due to introduction of reimbursement codes & impact of COVID pandemic

COVID has changed expectations on care delivery

• Estimates of pre-pandemic awareness of telehealth benefits has risen from 24% to 80%[3]

• Estimates over 1/3 of ambulatory visits could be done remotely[3]

• Telehealth[3] offers possibility for over 50 million Americans in remote areas access to routine healthcare

Reimbursement availability now a catalyst for adoption

• Introduction of Medicare reimbursement for Remote Patient Monitoring opened the professional market by creating clear financial incentives & a path to payment for physicians

• This was a ‘watershed’ moment; Medicare & Medicaid cover 1/3 of the patient universe with insurers covering remaining 2/3 typically following Medicare / Medicaid lead in coverage & payment

• 11% consumers using telehealth in 2019[2]

• 76% consumers indicated they were highly or moderately likely to use telehealth going forwards[2]

• 50-175x reported increase in health systems & practices reported use of telehealth[2]

• Estimated $250b market size[2]

• “...in April 2020, nearly half (43.5%) of Medicare primary care visits were provided through telehealth compared with less than one percent (0.1%) in February before the public health emergency [Covid-19]” [1]

• https://www.hhs.gov/about/news/2020/07/28/hhs-issues-new-report-highlighting-dramatic-trends-in-medicare-beneficiary-telehealth-utilization-amid-covid-19.html

• https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality#

• Lisa Gill JPM insights commentary https://www.jpmorgan.com/solutions/cib/insights/health-care-conference#insights

strategy

Opportunity NOW to transform Adherium to lead commercially valuable integrated management solutions

respiratory digital management ecosystem

==> picture [64 x 65] intentionally omitted <==

==> picture [310 x 192] intentionally omitted <==

----- Start of picture text -----

Adherence & Technique
Integrated respiratory
digital eco-system
Remote monitoring, real
time data capture
Cloud Platform collects
Data Reporting data across the patient Disruptive Technologies
population & identifies
patients requiring
intervention (by exception)
Wheeze Physiological Measures
----- End of picture text -----

Physiological Measures

evolution

==> picture [335 x 115] intentionally omitted <==

----- Start of picture text -----

Sensors
Portal
Adherence
Revenue generation
Healthcare providers & payers
Partner Summatix / Planet Innovation
for data aggregation / analysis
Population risk assessment
----- End of picture text -----

==> picture [65 x 65] intentionally omitted <==

==> picture [64 x 65] intentionally omitted <==

Phase 2

==> picture [169 x 8] intentionally omitted <==

----- Start of picture text -----

Adherence & Technique Data Reporting
----- End of picture text -----

Adherium

Phase 1

Assets from current and future discussions Now Assets from current Assets from current relationships relationships Adherium Hailie® Sensors Adherium Hailie® Sensors Adherium Hailie® Sensors Peak Flow Meter Peak Flow Meter Peak Flow Meter

Business with range of digital inhaler sensors & portal platform for adherence monitoring

Business based on a respiratory ecosystem providing a portal & software platform with architecture for the integration of proprietary & 3rd party digital sensors, connected devices & data management systems

==> picture [961 x 47] intentionally omitted <==

strategy

Positive progression with existing partners & product portfolio

Existing Partners

Current Portfolio

==> picture [109 x 29] intentionally omitted <==

Phase 1 training completed

Pilot Program of evaluations in specialist Asthma centers initiated Pilot read outs expected Q2 CY2021

Sensors

• Physiologically enabled sensor development progressing well (plan increases asthma/COPD device market coverage from 56% to 80% by US medication volume by H1 CY2022)

• Physiological measure proof of concept transferred to commercial product design

• Submission of first 510(k) of physiological enabled sensor expected Q1 CY 2021

==> picture [112 x 19] intentionally omitted <==

Finalist in “Australia by Design” Innovation Award TV series

Initial workflow assessment complete

Modifications made to patient materials & app in response to feedback Rescue inhaler patient population data collection ongoing

Software

• Migration of platform to Microsoft Azure[®] completed to deliver capacity & capability for scale-up

• Peak Flow meter integration expected early Q2 CY2021 as first step in ecosystem build

Primary activity from clinical trials & development contracts

Four clinical studies underway using Adherium sensors

Development projects upgrading patient user experience initiated

• App & portal upgrades enhanced user experience & data presentation for patients & physicians

• System architecture design allows integration of third party devices into the platform

strategy

Rapid acceleration in telehealth & digital monitoring reflected in increased partnering opportunities strengthening revenue stream potential with >10 ongoing commercial partnering engagements currently progressing at C suite level

==> picture [902 x 314] intentionally omitted <==

----- Start of picture text -----

Partner Type Disease/Population Management Partners CDMO’s Pharmaceutical Companies
Connected Health Solution PERS & RPM
Employer / Commercial Payers Plans Pharma / Biotech
Rationale Integrated Managed Care Consortia Medical Devices Inhaled Pharmaceuticals
Telemedicine / Virtual Care Providers Inhaled Pharmaceuticals
On-Line Pharmacies
Series of ongoing discussions in North
Potential to integrate Hailie [®] digital sensor Potential to provide complementary digital
Product America to provide Hailie [®] digital sensors
technology into CDMO products & leverage sensors alongside sponsor products &
Range & portal reporting to enhance existing care
Adherium portal with CDMO customers leverage Adherium portal
provision & remote patient monitoring
Adherium Sensor sales
Revenue Model Software licence fee (SaaS & PaaS)
Data licence fee
----- End of picture text -----

strategy

Ecosystem evolution enhances overall product proposition to end clinical providers & payors with multiple longitudinal data points, leverages portal platform, & extends revenue stream potential for individual & combination of assets beyond adherence alone

==> picture [906 x 366] intentionally omitted <==

----- Start of picture text -----

Ecosystem
Initial ecosystem of Adherium sensors plus 3rd Party Devices & Apps Second Phase under investigation
Build
COPD
Capnography
Product Adherium Sensors Peak Flow Meter Spirometer Wheeze Analysis exacerbations
COPD
predicator
Measures maximum
Measures lung function.
speed of expiration, Measures wheeze a
Volume of air inspired Extends offering in
assesses ability to breath symptom of airway
Monitors patient adherence (frequency, air out as an assessment of airway obstruction. & expired. Primarily for COPD patients obstruction in asthma. COPD & supports predictive analysis Extends offering in
Rationale date & time);inhaler Complementary Complementary of exacerbations. COPD & supports
Primarily used in asthma. diagnostic in conjunction predictive analysis
technique; physiological measures Complementary diagnostic assessment of disease control with with other parameters Application in asthma under of exacerbations
diagnostic assessment of adherence such as adherence, peak
investigation
control with adherence. flow & lung function
Portal platform leverage
Portal platform leverage
Digital device integration
6 sensors available today Peak flow sensor
assessment progressing. Initial pharmacy pilot & Point of care App with
with 56% coverage, build integration progressing.
Product Target commercially clinical trial evaluation device with integration to
to 9 with physiological Commercially available
Range available with portal being initiated in physician data peak flow data &
data capture giving 80% with portal integration integration from H2 Australia reporting biomarker data
coverage in H1 CY2022 from H1 CY2021
CY2021
Adherium Sensor sales
Revenue
Software licence fee (SaaS & PaaS)
Model
Data licence fee
----- End of picture text -----*

Significant potential for further ecosystem sensor device integration including digitised spacers, nebulizers, OPEP mucus secretion devices

*Physiological Measures available on second generation devices Q3/4 CY 2021

strategy

Business Evolution Road Map

CY Q3 2020 – Q2 2021 CY Q2 2021 – Q4 2021 CY 2022 Initial partner model Partner scale-up in US with Full expansion & platform 1 2 3 establishment/proof of concept revenue traction leverage in US & ex-US Validate channel partners Scale-up of HGE & Monaghan; initiate Accelerated US commercialisation industry partner activity with full portfolio Test operational model Progressive revenue growth Potential expanded scale-up ex-US Validate business model Increase penetration in COPD Assess next wave device development Limited initial sensor volumes & orders e.g. nebulisers/integrated sensors First wave sensors with physiological Appointment of key leadership roles in measures Potential multi-provider data US & CTO in Australia integration leverage & monetisation Complete market launch of full range of Contracting new industry partners physiological enabled sensor Scale ecosystem with further new sensors with progressive revenue Establish ecosystem framework & Limited highly selective ex-US activity growth initial sensor integration assessment Pilot ecosystem build with early roll out of 3 new integrated sensors

$1 8 m fundraise to progress beyond 2021 commercial evaluations

Disclaimer and forward looking statement

The material contained herein is of a general nature & has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or potential opportunities.

This presentation may contain budget information, forecasts & forward-looking statements in respect of which there is NO guarantee of future performance & which of themselves involve significant risks (both known & unknown). Actual results & future outcomes will in all likelihood differ from those outlined herein.

Forward-looking statements are statements that are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” & similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding market size, future results, regulatory approvals, production targets, sales, staffing levels etc. All of such statements are subject to risks & uncertainties, many of which are difficult to predict & generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information & statements. These risks & uncertainties include, but are not limited to: (i) the possible delays in & the outcome of product development, (ii) risks relating to possible partnering or other like arrangements, (iii) the potential for delays in regulatory approvals, (iv) the unknown uptake & market penetration of any potential

commercial products & (vi) other risks & uncertainties related to the Company’s prospects, assets / products & business strategy. This is particularly the case with companies such as Adherium which operate in the field of developing & commercialising medical devices & related services. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, & we do not undertake any obligation to revise & disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Additionally there are a number of factors, both specific to Adherium & of a general nature, which may affect the future performance of Adherium. There is no guarantee that Adherium will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward-looking statements will be realised.

==> picture [634 x 332] intentionally omitted <==

APRIL 2021

==> picture [191 x 35] intentionally omitted <==